Iterative cycles of design, make, test and analyze (DMTA) are at the core of early stage drug discovery. Medicinal chemistry is a critical component within small molecule drug discovery and involves the design of molecules, synthesis, testing via bioassays, and analysis of results. Strateos’ goal is to automate many of the operations to enable a chemist to work on multiple programs at the same time in parallel, greatly improving the process efficiencies and shortening cycle times.

To demonstrate the improved efficiencies of an automated DMTA cycle, Strateos virtually and physically integrated chemical and biological experimental components of the drug discovery process to enable researchers to select structures that can be prepared on automated systems and made available for follow-up biological testing, allowing for timely hypothesis testing and validation.

In our presentation, we will highlight our case study demonstrating automated reproducible synthesis of multiple analog compounds followed by downstream cell-based and biochemical assays in as little as 3-5 days.

In this presentation, you will learn: 

• The capabilities of Strateos’s 23 drug discovery automation modules, and how they can be accessed via the cloud from anywhere in the world

• Synergies enabled by full integration under the Strateos cloud-based software stack

• Lessons learned from over a year operating in production mode